hydroxychloroquine has been researched along with Atherogenesis in 11 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Hydroxychloroquine (HCQ), an anti-inflammatory drug, has been shown to have multiple pleiotropic actions relevant to atherosclerosis." | 7.81 | Impact of Hydroxychloroquine on Atherosclerosis and Vascular Stiffness in the Presence of Chronic Kidney Disease. ( Apostolov, EO; Bose, C; Fahmi, T; Karaduta, OK; Kaushal, GP; Segal, MS; Shah, SV; Shukla, AM, 2015) |
| "Hydroxychloroquine (HCQ) is an anti-rheumatic drug commonly used in the treatment of rheumatoid arthritis and systemic lupus erythematosus." | 6.84 | Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. ( Eklund, KK; Hartman, O; Kovanen, PT; Lehtonen, J; Sinisalo, J, 2017) |
| "Hydroxychloroquine (HCQ) is a cornerstone in treatment of SLE patients and has been thought to exert a broad spectrum of beneficial effects on disease activity, prevention of damage accrual, and mortality." | 6.58 | Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. ( Bortoluzzi, A; Cauli, A; Erre, GL; Floris, A; Mangoni, AA; Piga, M, 2018) |
| " Hydroxychloroquine prevented atherosclerosis progression mainly by reversing immune status abnormality caused by SLE." | 3.96 | Systemic lupus erythematosus aggravates atherosclerosis by promoting IgG deposition and inflammatory cell imbalance. ( Duan, XW; Liu, T; Niu, H; Shi, N; Silverman, GJ; Zhang, S, 2020) |
| " Hydroxychloroquine (HCQ), an anti-inflammatory drug, has been shown to have multiple pleiotropic actions relevant to atherosclerosis." | 3.81 | Impact of Hydroxychloroquine on Atherosclerosis and Vascular Stiffness in the Presence of Chronic Kidney Disease. ( Apostolov, EO; Bose, C; Fahmi, T; Karaduta, OK; Kaushal, GP; Segal, MS; Shah, SV; Shukla, AM, 2015) |
| "Hydroxychloroquine (HCQ) is an anti-rheumatic drug commonly used in the treatment of rheumatoid arthritis and systemic lupus erythematosus." | 2.84 | Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. ( Eklund, KK; Hartman, O; Kovanen, PT; Lehtonen, J; Sinisalo, J, 2017) |
| "Rheumatoid arthritis is a chronic, systemic inflammatory disease that carries an increased risk of mortality due to cardiovascular disease." | 2.72 | Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation. ( Chen, J; Cooper, D; Norling, LV, 2021) |
| "Hydroxychloroquine (HCQ) is a cornerstone in treatment of SLE patients and has been thought to exert a broad spectrum of beneficial effects on disease activity, prevention of damage accrual, and mortality." | 2.58 | Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. ( Bortoluzzi, A; Cauli, A; Erre, GL; Floris, A; Mangoni, AA; Piga, M, 2018) |
| "Atherothrombosis is no longer considered solely a disorder of lipoprotein accumulation in the arterial wall." | 2.50 | Anti-inflammatory therapies for cardiovascular disease. ( Lüscher, TF; Ridker, PM, 2014) |
| "Hydroxychloroquine (HCQ) has been reported to improve the lifespan and the prognosis of dyslipidaemia in patients with SLE, but the mechanism is unclear." | 1.72 | Supplemental hydroxychloroquine therapy regulates adipokines in patients with systemic lupus erythematosus with stable disease. ( Dobashi, H; Kadowaki, N; Kameda, T; Kato, M; Mino, R; Miyagi, T; Miyatake, N; Mizusaki, M; Nakashima, S; Shimada, H; Sugihara, K; Ueeda, K; Wakiya, R, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Wakiya, R | 1 |
| Ueeda, K | 1 |
| Shimada, H | 1 |
| Nakashima, S | 1 |
| Kameda, T | 1 |
| Miyatake, N | 1 |
| Kato, M | 1 |
| Miyagi, T | 1 |
| Sugihara, K | 1 |
| Mizusaki, M | 1 |
| Mino, R | 1 |
| Kadowaki, N | 1 |
| Dobashi, H | 1 |
| Ahmed, S | 1 |
| Konig, J | 1 |
| Kasselman, LJ | 1 |
| Renna, HA | 1 |
| De Leon, J | 1 |
| Carsons, SE | 1 |
| Reiss, AB | 1 |
| Liu, T | 1 |
| Shi, N | 1 |
| Zhang, S | 2 |
| Silverman, GJ | 1 |
| Duan, XW | 1 |
| Niu, H | 1 |
| Chen, J | 1 |
| Norling, LV | 1 |
| Cooper, D | 1 |
| Floris, A | 1 |
| Piga, M | 1 |
| Mangoni, AA | 1 |
| Bortoluzzi, A | 1 |
| Erre, GL | 1 |
| Cauli, A | 1 |
| Migkos, MP | 1 |
| Markatseli, TE | 1 |
| Iliou, C | 1 |
| Voulgari, PV | 1 |
| Drosos, AA | 1 |
| Ridker, PM | 1 |
| Lüscher, TF | 1 |
| Shukla, AM | 1 |
| Bose, C | 1 |
| Karaduta, OK | 1 |
| Apostolov, EO | 1 |
| Kaushal, GP | 1 |
| Fahmi, T | 1 |
| Segal, MS | 1 |
| Shah, SV | 1 |
| Hartman, O | 1 |
| Kovanen, PT | 1 |
| Lehtonen, J | 1 |
| Eklund, KK | 1 |
| Sinisalo, J | 1 |
| Mirjafari, H | 1 |
| Al-Husain, A | 1 |
| Bruce, IN | 1 |
| Belizna, CC | 1 |
| Richard, V | 1 |
| Thuillez, C | 1 |
| Lévesque, H | 1 |
| Shoenfeld, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Perioperative Inflammatory Response Assessment in High-risk Patients Undergoing Noncardiac Surgery - a Prospective Non-interventional Observational Study[NCT04753307] | 1,400 participants (Anticipated) | Observational | 2021-01-19 | Recruiting | |||
| The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study[NCT03222206] | Phase 4 | 34 participants (Actual) | Interventional | 2017-11-08 | Completed | ||
| Hydroxychloroquine for the Prevention of Recurrent Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial[NCT02648464] | Phase 4 | 125 participants (Actual) | Interventional | 2016-02-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for hydroxychloroquine and Atherogenesis
| Article | Year |
|---|---|
Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheuma | 2021 |
Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus.
Topics: Animals; Atherosclerosis; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Oxidative Stres | 2018 |
Anti-inflammatory therapies for cardiovascular disease.
Topics: Adaptive Immunity; Anti-Inflammatory Agents; Antioxidants; Atherosclerosis; C-Reactive Protein; Carr | 2014 |
Anti-inflammatory therapies for cardiovascular disease.
Topics: Adaptive Immunity; Anti-Inflammatory Agents; Antioxidants; Atherosclerosis; C-Reactive Protein; Carr | 2014 |
Anti-inflammatory therapies for cardiovascular disease.
Topics: Adaptive Immunity; Anti-Inflammatory Agents; Antioxidants; Atherosclerosis; C-Reactive Protein; Carr | 2014 |
Anti-inflammatory therapies for cardiovascular disease.
Topics: Adaptive Immunity; Anti-Inflammatory Agents; Antioxidants; Atherosclerosis; C-Reactive Protein; Carr | 2014 |
Cardiovascular risk factors in inflammatory arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Atherosclerosis; Cardiovascular Diseases; Clinical | 2011 |
Insights into atherosclerosis therapy in antiphospholipid syndrome.
Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents; Antibodies, Antiphospholipid; Antiphosph | 2007 |
2 trials available for hydroxychloroquine and Atherogenesis
| Article | Year |
|---|---|
Hydroxychloroquine Effects on THP-1 Macrophage Cholesterol Handling: Cell Culture Studies Corresponding to the TARGET Cardiovascular Trial.
Topics: Arthritis, Rheumatoid; Atherosclerosis; Cell Culture Techniques; Cholesterol; Humans; Hydroxychloroq | 2022 |
Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial.
Topics: Antirheumatic Agents; Atherosclerosis; Double-Blind Method; Humans; Hydroxychloroquine; Myocardial I | 2017 |
4 other studies available for hydroxychloroquine and Atherogenesis
| Article | Year |
|---|---|
Supplemental hydroxychloroquine therapy regulates adipokines in patients with systemic lupus erythematosus with stable disease.
Topics: Adipokines; Adiponectin; Adult; Antibodies, Antinuclear; Antirheumatic Agents; Atherosclerosis; Cyto | 2022 |
Systemic lupus erythematosus aggravates atherosclerosis by promoting IgG deposition and inflammatory cell imbalance.
Topics: Animals; Atherosclerosis; Dendritic Cells; Disease Models, Animal; Disease Progression; Female; Hydr | 2020 |
Effect of hydroxychloroquine on the lipid profile of patients with Sjögren syndrome.
Topics: Aged; Antirheumatic Agents; Atherosclerosis; Dyslipidemias; Female; Humans; Hydroxychloroquine; Lipi | 2014 |
Impact of Hydroxychloroquine on Atherosclerosis and Vascular Stiffness in the Presence of Chronic Kidney Disease.
Topics: Animals; Aorta; Atherosclerosis; Bilirubin; Blood Glucose; Elasticity; Hydroxychloroquine; Inflammat | 2015 |